We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New AI Algorithm Predicts Which Breast Cancer Patients Can Benefit From Additional Therapy

By HospiMedica International staff writers
Posted on 01 Jan 2020
Researchers from the Case Western Reserve University (Cleveland, OH, USA) have developed a new artificial intelligence (AI) algorithm that could help better determine which patients diagnosed with the pre-malignant breast cancer (commonly referred to as stage 0) are likely to progress to invasive breast cancer and might benefit from additional therapy over and above surgery alone.

Stage 0 breast cancer is the most common type and known clinically as ductal carcinoma in situ (DCIS), indicating that the cancer cell growth starts in the milk ducts. More...
Once a lumpectomy of breast tissue reveals this pre-cancerous tumor, most women have surgery to remove the remainder of the affected tissue and some are given radiation therapy as well.

The researchers used a computer program to analyze the spatial architecture, texture and orientation of the individual cells and nuclei from scanned and digitized lumpectomy tissue samples from 62 DCIS patients. They found that both the size and orientation of the tumors characterized as “indeterminate” were actually much closer to those confirmed as low risk for recurrence by an expensive genetic test called Oncotype DX. The researchers then validated the features that distinguished the low and high risk Oncotype groups in being able to predict the likelihood of progression from DCIS to invasive ductal carcinoma in an independent set of 30 patients.

“Current testing places patients in high risk, low risk and indeterminate risk—but then treats those indeterminates with radiation, anyway,” said Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at the Case School of Engineering. “They err on the side of caution, but we’re saying that it appears that it should go the other way—the middle should be classified with the lower risk. “In short, we’re probably overtreating patients. That goes against prevailing wisdom, but that’s what our analysis is finding.”

Related Links:
Case Western Reserve University


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Digital Radiography System (Ceiling Free)
Digix CF Series
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.